Common use of LIST OF ATTACHMENTS Clause in Contracts

LIST OF ATTACHMENTS. Attachment A: Responsible Persons and Contact Information Attachment B: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT A Responsible Persons and Contact Information AKERO Name Email Address Contact Number Responsibility [***] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT B AMGEN Disposition Package The following documents are to comprise the AMGEN Disposition Package to support the release of the Product to AKERO: Stage of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CHANGE SUMMARY

LIST OF ATTACHMENTS. Attachment AAppendix A Collective Bargaining Agreement (2019-2021) Appendix B NYS Labor Board Certification Appendix C Definitions Appendix D Mission Statement Appendix E Chairperson Stipend Schedule Appendix F Evaluation of Faculty Classroom Performance Appendix G Online Course Peer Evaluation Appendix H Annual Faculty Activity Report Appendix I Memorandum of Understanding dated July 1, 2007 Appendix J Alternative Faculty Responsibility Program – CPS and TCB, Professor of the Practice Appendix K Faculty Directors & Coordinators APPENDIX A Collective Bargaining Agreement (2019-2021) APPENDIX B NEW YORK STATE LABOR RELATIONS BOARD In the Matter of : Responsible Persons and Contact Information Attachment B: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”ST. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY XXXX’S UNIVERSITY, NEW YORK : DECISION NO. 12630 : : : : CASE NOS. SE 43696 : SE 43727 : : : : -and- FACULTY ASSOCIATION AT ST. JOHN’S UNIVERSITY ST. XXXX’S CHAPTER OF THE SECURITIES AMERICAN ASSOCIATION OF UNIVERSITY PROFESSORS O R D E R AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT CERTIFICATION OF 1933REPRESENTATIVES Upon the following papers herein: Dates Petition filed by Faculty Association at St. John’s University (Case No. SE 43696) December 22, AS AMENDED. ATTACHMENT A Responsible Persons and Contact Information AKERO Name Email Address Contact Number Responsibility [***] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT B AMGEN Disposition Package The following documents are to comprise the AMGEN Disposition Package to support the release 1969 Petition filed by St. John’s Chapter of the Product American Association of University Professors (Case No. SE 43727) January 12, 1970 Agreement for Consent Election February 6, 1970 Report Upon Secret Ballot February 27, 1970 Report Upon Secret Ballot (Run-off) March 24, 1970 Notice of Hearing to AKERO: Stage determine the validity of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 7certain challenges April 10, 2018 Agreed 1970 AND, the Petitioners in Case No. SE-43696 and accepted for: Agreed Case No. SE-43727 having jointly moved in writing filed April 20, 1970 for an Order treating their petitions as a joint petition and accepted for: AKERO THERAPEUTICScertifying them as the bargaining representative of the employees in the appropriate bargaining unit as set forth in the Agreement for Consent Election and the Notices of Election; AND, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CHANGE SUMMARYthe Employer having consented to the granting of the motion,

LIST OF ATTACHMENTS. Attachment This Agreement includes the following documents, which are attached and incorporated herein by reference: ATTACHMENT A: Responsible Persons and Contact Information Attachment TECHNICAL SPECIFICATIONS; ATTACHMENT B: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS PAYMENT SCHEDULE; ATTACHMENT C: PRICING BREAKDOWN / OPTION PRICING; ATTACHMENT D: DELIVERABLE SCHEDULE; ATTACHMENT E: LIQUIDATED DAMAGES; ATTACHMENT F: FORM OF THIS EXHIBIT WERE OMITTED SUPPLY BOND; ATTACHMENT G: FORM OF LETTER OF CREDIT; ATTACHMENT H: FORMS OF WAIVER AND REPLACED WITH “[***]”. A COMPLETE VERSION RELEASE FOR PARTIAL AND FINAL PAYMENTS; ATTACHMENT I: FORM OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY INSURANCE CERTIFICATE; ATTACHMENT J: STATEMENT OF THE SECURITIES LOWER TIER SUBCONTRACTORS AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT SUPPLIERS; ATTACHMENT K: APPROVED SUBCONTRACTORS LIST; ATTACHMENT L: HAZARDOUS COMMUNICATION COMPLIANCE; ATTACHMENT M: HAZARDOUS WASTE ADDENDUM; ATTACHMENT N: SELLER’S ELECTRONIC XXXX OF 1933, AS AMENDEDMATERIALS; ATTACHMENT O: OSSQ REQUIREMENTS; ATTACHMENT P: FORM OF CORPORATE GUARANTY; and ATTACHMENT Q: FORM OF PROGRESS REPORT. ATTACHMENT A Responsible Persons R: CARGO SURVEY REQUIREMENTS (WHEN REQUIRED BY SCOPE). [ADDITIONAL ATTACHMENTS AS REQUIRED PER PRIME CONTRACT] MATERIAL CONTRACT THIS AGREEMENT ("Agreement") is made this XX day of [Month], 20XX (“Effective Date”) by and Contact Information AKERO between [Seller's Legal Name Email Address Contact Number Responsibility and Address] (“Seller”) and [***Contractor's Legal Name and Address] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH (“[***]Contractor”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT B AMGEN Disposition Package The following documents are to comprise the AMGEN Disposition Package to support the release of the Product to AKERO: Stage of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CHANGE SUMMARY).

LIST OF ATTACHMENTS. Attachment AXerox CORPORATION Presstek By: Responsible Persons and Contact Information Attachment B/s/ Gerhard Moll By: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”/s/ Robert W. Hallman ---------------------------------- ---------------------------------- Name: Gerhard Moll Name: Robert W. Hallman -------------------------------- -------------------------------- Title: Sr. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT A Responsible Persons and Contact Information AKERO Name Email Address Contact Number Responsibility [***] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version dateVPGM Color Solutions Title: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICSCEO ------------------------------- ------------------------------- AMENDED SERVICE AGREEMENT BETWEEN PRESSTEK, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS AND XEROX CORPORATION EXHIBIT WERE OMITTED AND REPLACED WITH “J-1 ----------- (PROVIDED FOR REFERENCE ONLY) ----------------------------- [***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933REQUESTED]/*/ ---------------------------- /*/[CONFIDENTIAL TREATMENT REQUESTED] Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Commission pursuant to Rule 24b-2 promulgated under the Securities and Exchange Act of 1934, AS AMENDEDas amended. ATTACHMENT B AMGEN Disposition Package The following documents are AMENDED SERVICE AGREEMENT between PRESSTEK, Inc. and XEROX Corporation EXHIBIT J-2 ----------- EXHIBIT J-2 CUSTOMER SUPPORT OFFERINGS "DRAFT VERSION" 02/16/01 ALL INCLUSIVE COVERAGE Coverage for complete system including press components* Available M-F [CONFIDENTIAL TREATMENT REQUESTED]/*/ Docucolor 233: [CONFIDENTIAL TREATMENT REQUESTED]/*/ Docucolor 400: [CONFIDENTIAL TREATMENT REQUESTED]/*/ DIGITAL/ELECTRONICS SUPPORT COVERAGE Coverage for all DI and Electronic related components Available M-F [CONFIDENTIAL TREATMENT REQUESTED]/*/ Docucolor 233: [CONFIDENTIAL TREATMENT REQUESTED]/*/ Docucolor 400: [CONFIDENTIAL TREATMENT REQUESTED]/*/ AFTER HOURS TELEPHONE TECHNICAL SUPPORT (Optional addition to comprise CSA) 24x5 Coverage: [CONFIDENTIAL TREATMENT REQUESTED]/*/ 24x7 Coverage: [CONFIDENTIAL TREATMENT REQUESTED]/*/ BASIC TELEPHONE TECHNICAL SUPPORT 8x5 Coverage: [CONFIDENTIAL TREATMENT REQUESTED]/*/ 24x5 Coverage: [CONFIDENTIAL TREATMENT REQUESTED]/*/ 24x7 Coverage: [CONFIDENTIAL TREATMENT REQUESTED]/*/ BASIC SUPPORT COVERAGE Labor [CONFIDENTIAL TREATMENT REQUESTED]/*//hour M-F [CONFIDENTIAL TREATMENT REQUESTED]/*/ Overtime [CONFIDENTIAL TREATMENT REQUESTED]/*//hour Holidays [CONFIDENTIAL TREATMENT REQUESTED]/*//hour Travel up to 8 hours [CONFIDENTIAL TREATMENT REQUESTED]/*//hour Travel after 8 hours [CONFIDENTIAL TREATMENT REQUESTED]/*//hour Weekend Travel [CONFIDENTIAL TREATMENT REQUESTED]/*//hour Parts Variable pricing Telephone Support [CONFIDENTIAL TREATMENT REQUESTED]/*/ per incident OPTIONAL TRAINING On-Site press or pre-press training [CONFIDENTIAL TREATMENT REQUESTED]/*/ Per Person* Classroom press or pre-press training [CONFIDENTIAL TREATMENT REQUESTED]/*/ Per Person* * plus travel expenses ** minimum of 3 people, maximum of 5 people per training session. ---------------------------- /*/[CONFIDENTIAL TREATMENT REQUESTED] Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the AMGEN Disposition Package Commission pursuant to support Rule 24b-2 promulgated under the release Securities and Exchange Act of the Product to AKERO: Stage of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 71934, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICSas amended. EXHIBIT J-2 ================================================================================ PRESSTEK, INC. AMGEN INC. ByCUSTOMER ID# 55 Executive Drive Hudson, NH 03051-4903 x-xxxx: /s/ Xxxxxxxx Xxxxx Byxxxxxxxxxx@xxxxxxxx.com -------------------------------------------------------------------SUPPORT------ "DRAFT VERSION" 02/16/01 Information CUSTOMER Inst Name Date 02/16/2001 -------------------------------------------- ---------------- Address Agreement # ---------------------------------------------- --------- City State ZIP Rep C. Arfwedson ---------------------- ---- ------ ----------------- Phone PO# --------------------- ----------------- Fax Contact Name ------------------ ----------------- Bill to Name Bill to XX# ----------------------------------------- -------- Bill to Address E-mail axxxxss --------------------------------------- ------ City State ZIP SUPPORT CHOICES: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “--------------------------- ---- -------- All Inclusive [ ] Phone Fax Digital/ -------------------------- ------------------ Electronics [ ] Contact Name ----------------------------------------- --------------------------------------------------------------------------------------------- QTY PART# ESCRIPTION SERIAL # INSTALL DATE START DATE END DATE UNIT PRICE TOTAL --------------------------------------------------------------------------------------------- 1 Docucolor 233 System [***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933REQUESTED]/*/ (All Inclusive Coverage) 1 Docucolor 400 System [CONFIDENTIAL TREATMENT REQUESTED]/*/ (Digital/Electronics Coverage) --------------------------------------------------------------------------------------------- Sub Total ------------- ----------------------- Taxes State ----------------------- ----------------------- TOTAL $0.00 ----------------------- ============================================== PAYMENT DETAILS o Annual Check #_______________ o Bi-Annual Credit Card___________ o Quarterly CC Exp. Date__________ Customer:_____________________________________ ===================== Signature:____________________________________ Presstek Date:_________________________________________ Signature ___________ ===================== ============================================== Effective Date:______ Presstek Inc. agrees to provide and Customer agrees to accept the support agreement shown above according to the terms and conditions attached to this agreement. This agreement is the complete agreement between the parties for support on the date set forth above. ================================================================================ Total Price may or may not include state and local taxes which will be added to invoicing. ---------------------------- /*/[CONFIDENTIAL TREATMENT REQUESTED] Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Commission pursuant to Rule 24b-2 promulgated under the Securities and Exchange Act of 1934, AS AMENDEDas amended. CHANGE SUMMARYALL INCLUSIVE SYSTEM MAINTENANCE AND SOFTWARE SUPPORT TERMS AND CONDITIONS

LIST OF ATTACHMENTS. Attachment This Agreement includes the following documents, which are attached and incorporated herein by reference: ATTACHMENT A: Responsible Persons and Contact Information Attachment TECHNICAL SPECIFICATIONS; ATTACHMENT B: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS PAYMENT SCHEDULE; ATTACHMENT C: PRICING BREAKDOWN / OPTION PRICING; ATTACHMENT D: DELIVERABLE SCHEDULE; ATTACHMENT E: LIQUIDATED DAMAGES; ATTACHMENT F: FORM OF PERFORMANCE AND PAYMENT BOND; ATTACHMENT G: FORM OF LETTER OF CREDIT; ATTACHMENT H: FORM OF LIEN WAIVERS; ATTACHMENT I: FORM OF INSURANCE CERTIFICATE; ATTACHMENT J: STATEMENT OF LOWER TIER SUBCONTRACTORS AND SUPPLIERS; ATTACHMENT K: APPROVED SUBCONTRACTORS LIST (as applicable); ATTACHMENT L: HAZARDOUS COMMUNICATION COMPLIANCE; ATTACHMENT M: HAZARDOUS WASTE ADDENDUM; ATTACHMENT N: SUBCONTRACTOR’S ELECTRONIC XXXX OF MATERIALS; ATTACHMENT O: OSSQ REQUIREMENTS (QUALITY PLAN); ATTACHMENT P: HSE SUPPLEMENT; ATTACHMENT Q: PROJECT SITE SPECIFIC SAFETY PLAN; ATTACHMENT R: PROJECT LABOR AGREEMENT (if applicable); ATTACHMENT S: INSPECTION TEST PLAN; ATTACHMENT T: CARGO SURVEY REQUIREMENTS; and ATTACHMENT U: UTILITY AND TEMPORARY FACILITY REQUIREMENTS. [ADDITIONAL ATTACHMENTS AS REQUIRED PER PRIME CONTRACT] SUBCONTRACT THIS EXHIBIT WERE OMITTED AND REPLACED WITH AGREEMENT (“Agreement”) is made this XX day of [***Month], 20XX (“Effective Date”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT A Responsible Persons ) by and Contact Information AKERO between [Subcontractor’s Legal Name Email Address Contact Number Responsibility and Address] (“Subcontractor”) and [***Contractor’s Legal Name and Address] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH (“[***]Contractor”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT B AMGEN Disposition Package The following documents are to comprise the AMGEN Disposition Package to support the release of the Product to AKERO: Stage of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CHANGE SUMMARY).

LIST OF ATTACHMENTS. Attachment A: Responsible Persons and Contact Information Attachment B: AMGEN Disposition Package CERTAIN CONFIDENTIAL PORTIONS INFORMATION SCHEDULE - AUTHORIZED OFFICERS EXHIBIT A -- FORM OF THIS PRIVATE SHELF NOTE EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION B -- FORM OF THIS REQUEST FOR PURCHASE EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY C -- FORM OF CONFIRMATION OF ACCEPTANCE EXHIBIT D-1 -- FORM OF OPINION OF COMPANY’S SPECIAL COUNSEL EXHIBIT D-2 -- FORM OF OPINION OF THE SECURITIES SUBSIDIARY GUARANTOR’S SPECIAL LOCAL COUNSEL EXHIBIT D-3 -- FORM OF DUTCH OPINION EXHIBIT E -- FORM OF CONSENT AND EXCHANGE COMMISSION PURSUANT ACKNOWLEDGEMENT EXHIBIT F -- CERTIFICATE AS TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT REPRESENTATIONS, DEFAULTS, ETC. EXHIBIT G -- FORM OF 1933, AS AMENDED. ATTACHMENT A Responsible Persons and Contact Information AKERO Name Email Address Contact Number Responsibility [***] [***] [***] [***] AMGEN Name Email Address Contact Number Responsibility [***] [***] [***] [***] Exhibit A version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICSSUBSIDIARY GUARANTY AGREEMENT SCHEDULE 6B(1) -- LIST OF EXISTING LIENS SCHEDULE 8G -- LIST OF AGREEMENTS RESTRICTING DEBT FRANKLIN ELECTRIC CO., INC. AMGEN INCFRANKLIN ELECTRIC B.V. 0000 Xxxxxxxxx Xxxx Fort Xxxxx, Indiana 46809 As of July 30, 2021 To: PGIM, Inc. (herein called “Prudential”) Each Prudential Affiliate which becomes bound by this Agreement as hereinafter provided (together with Prudential, the “Purchasers”) c/o Prudential Capital Group Xxx Xxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxx, Xxxxxxxx 00000 Ladies and Gentlemen: The undersigned, Franklin Electric Co., Inc., an Indiana corporation (herein called the “Company”) and Franklin Electric B.V., a Netherlands private company with limited liability (the “Dutch Subsidiary Issuer”), hereby agree with you as set forth below. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT B AMGEN Disposition Package The following documents are Reference is made to comprise the AMGEN Disposition Package to support the release paragraph 10 hereof for definitions of the Product to AKERO: Stage of Manufacture Disposition Package Documents Drug Substance Manufacture CoA CoC Nonconformance’s lot summary report Attachment B version date: June 7, 2018 Agreed and accepted for: Agreed and accepted for: AKERO THERAPEUTICS, INC. AMGEN INC. By: /s/ Xxxxxxxx Xxxxx By: /s/ Xxxx Xxxxx Name: Xxxxxxxx Xxxxx Name: Xxxx Xxxxx Title: President Title: Director, Quality Date: June 7,2018 Date: June 7, 2018 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CHANGE SUMMARYcapitalized terms used herein.